Eli Lilly's stock surged after a strong Q1 report with revenue up 55.55% year-over-year and raised full-year guidance, yet it remains down 10% year-to-date. The company’s GLP-1 drugs Mounjaro and Zepbound showed significant growth, but pricing pressures and political risks loom. While some investors consider trimming gains tactically due to valuation and margin concerns, the strong pipeline and analyst optimism support holding core positions. Long-term holders may use covered calls or stop-loss strategies while watching for re-entry points and upcoming events like the 2026 Investment Community Meeting.
The global colorectal cancer diagnostics and therapeutics market is projected to grow at a compound annual growth rate (CAGR) of approximately 9% from 2026 to 2034, reaching an estimated value of $73 billion by 2034. This growth is driven by rising c...
Eli Lilly released positive results from two late-stage obesity studies showing that patients maintained significant weight loss after switching to either Foundayo or a lower dose of Zepbound. The SURMOUNT-MAINTAIN trial showed continued weight loss ...
Eli Lilly's late-phase trials SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN show that adults with obesity maintained most of their weight loss after switching from high doses of injectable therapies Wegovy and Zepbound to either oral Foundayo or lower-dose Z...
Nvidia's market capitalization recently exceeded $5.3 trillion, surpassing the combined value of all 59 healthcare companies in the S&P 500, which total about $5.2 trillion. This shift highlights the massive investor confidence in AI infrastructure, ...
Eli Lilly launched a charitable initiative supporting community organizations to distribute 500,000 nutritious meals across 15 U.S. communities as part of its 150th anniversary. The company also funds cold storage infrastructure for 150 food pantries...
